Creating an Amorphous Solid Dispersion (ASD) is an increasingly popular way of improving Active Pharmaceutical Ingredient (API) solubility. But while the approach can be successful, the big problem is demonstrating ASD stability, preventing ingredients in the amorphous phase becoming (crystallized, and ensuring performance in In-Vivo). In this webinar we will set out the scientific challenges and the cutting edge solutions available in the lab.
Jim Jingjun Huang, Principle Scientist, Hoffmann- La Roche
Moderator: Zachary Brennan, Editor, in-PharmaTechnologist.com and Outsourcing-Pharma.com